Anthony E. Maida Joins Replicon Technologies Inc. as President/CEO.Business Editors & Health/Medical Writers BIOWIRE2K DANVILLE, Calif.--(BW HealthWire)--Jan. 7, 2002 Replicon rep·li·con n. A genetic element that undergoes replication as an autonomous unit. Technologies Inc. (RTI RTI - Return from interrupt ) today announced that Anthony E. Maida, III, MS, MBA MBA abbr. Master of Business Administration Noun 1. MBA - a master's degree in business Master in Business, Master in Business Administration has joined the company as president and chief executive officer. Maida has extensive experience leading companies in the clinical development of oncology products, and in the last 12 months has raised over $36 million dollars for biotechnology companies. Prior to joining RTI, Maida served as chairman, chief executive officer, founder and director of BioConsul Drug Development Corp. of Danville, whose mission is to acquire, develop and ultimately divest promising biotechnology and pharmaceutical products and/or early stage companies through a proven business strategy known as Leveraged Venture Resource Management(c). During this period, Maida was responsible for securing financing and served as acting president of CancerVax Corp., a Carlsbad, Calif. company focused on the research, development and commercialization of immunotherapeutic products for the treatment of cancer. Maida also served as CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. during the organizational phase of Trellis 1. Trellis - An object-oriented language from the University of Karlsruhe(?) with static type-checking and encapsulation. 2. Trellis - An object-oriented application development system from DEC, based on the Trellis language. (Formerly named Owl). Bioscience Inc., a visual proteomics company that received financing in October 2001. From 1992 to 1999, Maida was president and chief executive officer of Jenner Biotherapies Inc., where he was responsible for bringing four products into the clinic, secured more than 130 patents and patent applications and negotiated over 30 licensing and service agreements while expending a total inception-to-date of $16.5 million over seven years. From 1990 to 1992, Maida provided leadership to two biotechnology companies: CellPath Inc., where he was president and chief executive officer' and Prototek Inc., where he was vice president/chief financial officer. Maida received a BA in history from the University of Santa Clara in 1975, a BA in biology from San Jose State University in 1977, an MS in toxicology from San Jose State University in 1986, and a MBA from Santa Clara University in 1978. Replicon Technologies Inc. (www.replicontechnologies.com) is a biopharmaceutical company focused on developing therapeutic applications of replicons for human tumors. RTI is in the process of manufacturing the replicons under conditions suitable for delivery to brain tumor Brain Tumor Definition A brain tumor is an abnormal growth of tissue in the brain. Unlike other tumors, brain tumors spread by local extension and rarely metastasize (spread) outside the brain. patients and expects to enter Phase I/II Clinical trials in 2003. RTI's corporate headquarters are in Danville; research and manufacturing operations are located at the OADI OADI Office for the Advancement of Developing Industries (University of Alabama-Birmingham) Technology Center, a small business incubator affiliated with the University of Alabama at Birmingham UAB began in 1936 as the Birmingham Extension Center of the University of Alabama. Because of the rapid growth of the Birmingham area, it was decided that an extension program for students who had difficulties which prevented them from studying in Tuscaloosa was needed. . |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion